Our expertise research and development spans the entire life-cycle of a medicine. We have capabilities in both small molecules and biologics. This allows us to search for solutions to unmet medical needs using both modalities, individually or in combination
AstraZeneca & Karolinska Institutet: A new industry - academia partnership model
An IMED Collaboration Update
AstraZeneca has collaborated with Karolinska Institutet in Sweden, one of the world’s leading medical research universities, for many years on different projects. In 2013, we created a joint centre for research on cardiovascular and metabolic diseases. This goes deeper than the usual industry/academia partnership, as scientists from both partners work side-by-side in a dedicated university unit to develop new therapies for people in need. The ICMC aims to identify and validate novel targets within cardio-metabolic diseases, focusing on three strategic research areas: heart failure, diabetes and chronic kidney disease across both small molecules and biologics.Download collaboration update (PDF 421kb)
All Directors are collectively responsible for the success of AstraZeneca. Discover general information, images and biographies of our Board of Directors.
AstraZeneca's pipeline is one of the most exciting in the industry. Download the latest version of our development pipeline.
Path to new medicines
The discovery, development and commercialisation of a medicine is a complex process. Information on our path to new medicines and an interactive overview are available.
Visit our dedicated neuroscience site for more information on our research and partnering in the area.
Visit our Open Innovation site to see how we collaborate to push the boundaries of science and deliver life-changing medicines